ATB Therapeutics, an Aye, Belgium-based company developing therapeutic antibody pipeline derived from its proprietary ATBioFarm platform, raised €54M in Series A funding.
The round was led by EQT Life Sciences through its LSP 7 fund and MRL Ventures Fund with participation from V-Bio, VIVES Partners, the Belgian sovereign fund SFPIM, Wallonie Entreprendre, Sambrinvest, and existing investors.
The company intends to use the funds to expand and enhance the ATBioFarm platform, as well as to accelerate development of its weaponized antibodies for oncology and immunology applications.
Led by CEO Bertrand Magy, ATB Therapeutics is dedicated to providing biologics that incorporate novel cell-killing mechanisms, including enzymatic functionalities, within targeted antibodies. These rapidly produced antibodies combine multiple targeting and killing domains, enhancing their effectiveness and safety compared to traditional conjugates. The ATBioFarm technology facilitates the scalable, single-step production of these biologics, promising significant advancements across various therapeutic applications.
ATB’s research and development operations will be extended to Ghent and will continue in Marche-en-Famenne, where the Company is setting up a pilot manufacturing facility.
In conjunction with this funding, Mark Throsby has been appointed ATB’s Executive Chairman.
FinSMEs
18/11/2024